Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (344)	2/23/2003 4:58:09 AM
From: Icebrg	Read Replies (2) \| Respond to of 631

CYTOKINE BLOCKERS. Those small but potent messenger proteins, cytokines, have become the drug targets of choice in rheumatoid arthritis following the extravagant success of Enbrel and Remicade, which both inhibit the action of tumor necrosis factor. Cytokine blockade, once considered a sure loser, is now wildly popular and biotech and pharmaceutical companies alike are testing intriguing new therapies in the clinic – including an array of interleukin-blockers, more than a few p38 MAP kinase inhibitors and a handful of small molecules intended to block cytokine production per se. Each has potential, but cytokine blockade, as these companies are discovering, can have unexpected and unpleasant consequences. Only a lucky few of these drugs will survive the perils to emerge winners.... The latest Signals Mag article is a write-up on various cytokine-related approaches to treat RA. signalsmag.com